The liquid biopsy specialist said its test was based on analytical and clinical validation studies that included more than 7,500 samples and 30,000 unique variants across over 30 cancer types.
News Editor Amanda Pedersen shares her take on the Trump administration's decision to limit FDA regulation of lab-developed tests.
These were the healthcare-related statements that grabbed our attention during the 2020 Democratic National Convention.
Join News Editor Amanda Pedersen on Tuesday via Facebook Live for a candid discussion about President Trump's attempt to bar FDA from regulating laboratory tests. The Medtech Unfiltered live stream will begin at 8 a.m. PST / 11 a.m. EST.
The move comes as FDA has put a potential pause on an EUA for convalescent plasma – a therapy President Trump has championed - to treat COVID-19.
While some believe cutting ties with China would serve as an impetus for more goods to be made in America, some medtech leaders think it could be disastrous — especially during a pandemic.